Company Overview
Snapshot
Founded in December 2024 by Marvin Collin, Rami Cohen, and Raphael Nir, Ascento-CDA operates with 1–10 employees. The company has raised $350,000 across one funding round. In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline.
Business overview
Ascento-CDA is a healthcare analytics company focused on building a scalable platform for the early detection of dementia and diabetes. Its proprietary analytic engine integrates immunology data, retinal imaging signals, and cognitive assessments to identify biologic activity years before symptoms manifest. The platform aims to transform existing data streams into actionable intelligence, reclassifying hidden risk in patients and enabling earlier, more targeted interventions. Ascento-CDA serves insurers, payers, and health providers, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, leveraging Artificial Intelligence and Machine Learning.
Strategic signal
In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline using inflammatory, immunologic, and cognitive mapping (IICM™). This publication provides scientific validation for the company's core technology and approach, signaling to investors and the healthcare industry its potential to advance pre-clinical disease detection and address significant cost drivers in global healthcare.
Log in to access full profile ›Company Intelligence Q&A
- When was Ascento-CDA founded?
- Ascento-CDA was founded in December 2024.
- What is Ascento-CDA's primary focus?
- Ascento-CDA focuses on the early detection of dementia and diabetes by identifying biologic activity years before symptoms appear, leveraging a scalable healthcare analytics platform.
- What was a key scientific development for Ascento-CDA?
- In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline using Inflammatory, Immunologic and Cognitive Mapping (IICM™).
- What technology does Ascento-CDA utilize?
- Ascento-CDA utilizes Artificial Intelligence and Machine Learning within its proprietary analytic engine to integrate immunology data, retinal imaging signals, and cognitive assessments.
- What markets does Ascento-CDA target?
- Ascento-CDA targets the North American market, serving healthcare providers, insurance companies, and patients.